Ajay Dhakal

Hematology

601 Elmwood Ave
Rochester, NY 14642

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 33 publications

Postradiation angiosarcoma of the breast: a 25-year single-institution analysis of clinicopathological characteristics and immunohistochemical biomarker study.

Postradiation angiosarcoma of the breast: a 25-year single-institution analysis of clinicopathological characteristics and immunohistochemical biomarker study.

Journal: Biotechnic & histochemistry : official publication of the Biological Stain Commission

Published: February 16, 2026

Pursuit of precision oncology in the treatment of metastatic hormone receptor-positive breast cancer: Making strides or barely moving?

Pursuit of precision oncology in the treatment of metastatic hormone receptor-positive breast cancer: Making strides or barely moving?

Journal: CA: a cancer journal for clinicians

Published: January 12, 2026

Phase 2 trial of exercise and low-dose ibuprofen for cancer-related cognitive impairment in patients receiving chemotherapy.

Phase 2 trial of exercise and low-dose ibuprofen for cancer-related cognitive impairment in patients receiving chemotherapy.

Journal: Cancer

Published: July 24, 2025

Biology is Queen: The Oncotype DX 21-Gene Recurrence Score Has Stronger Prognostic Ability than Lymph Node Burden for Patients with Breast Cancer.

Biology is Queen: The Oncotype DX 21-Gene Recurrence Score Has Stronger Prognostic Ability than Lymph Node Burden for Patients with Breast Cancer.

Journal: Annals of surgical oncology

Published: June 09, 2025

Consortium for Intracranial Metastasis Academic Research (CIMARa): Global interdisciplinary collaborations to improve outcomes of patient with brain metastases.

Consortium for Intracranial Metastasis Academic Research (CIMARa): Global interdisciplinary collaborations to improve outcomes of patient with brain metastases.

Journal: Neuro-oncology advances

Published: April 25, 2025

Efficacy of trastuzumab deruxtecan in treating HER2-low breast cancer leptomeningeal metastasis: a case report.

Efficacy of trastuzumab deruxtecan in treating HER2-low breast cancer leptomeningeal metastasis: a case report.

Journal: Personalized medicine

Published: November 20, 2024

Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study.

Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: September 06, 2024

Effect of Breast Cancer Receptor Subtypes and CSF Cytology Status on Survival of Patients With Leptomeningeal Disease.

Effect of Breast Cancer Receptor Subtypes and CSF Cytology Status on Survival of Patients With Leptomeningeal Disease.

Journal: Clinical breast cancer

Published: May 03, 2024

Breast Cancer With HER2 Immunohistochemical Score 2 and Average HER2 Signals/Cell 6 or More and HER2/CEP17 Ratio Less Than 2 ('ISH Group 3'): A Multi-Institutional Cohort Analysis Emphasizing Outcome and Molecular Subtype.

Breast Cancer With HER2 Immunohistochemical Score 2 and Average HER2 Signals/Cell 6 or More and HER2/CEP17 Ratio Less Than 2 ('ISH Group 3'): A Multi-Institutional Cohort Analysis Emphasizing Outcome and Molecular Subtype.

Journal: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

Published: April 01, 2024

Impact of systemic disease on CNS disease control after stereotactic radiosurgery to breast cancer brain metastases (The SYBRA Study).

Impact of systemic disease on CNS disease control after stereotactic radiosurgery to breast cancer brain metastases (The SYBRA Study).

Journal: NPJ breast cancer

Published: February 29, 2024

Oral SERD, a Novel Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer.

Oral SERD, a Novel Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer.

Journal: Cancers

Published: November 24, 2023

HER2 categorical changes after neoadjuvant chemotherapy: A study of 192 matched breast cancers with the inclusion of HER2-Low category.

HER2 categorical changes after neoadjuvant chemotherapy: A study of 192 matched breast cancers with the inclusion of HER2-Low category.

Journal: Human pathology

Published: September 17, 2023

Showing 1-12 of 33

Last Updated: 09/26/2026